《来自南锡和米兰队列的炎症性肠病患者的 COVID-19 发病和模式》。
Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts.
机构信息
Humanitas Clinical and Research Center, Istituto di ricovero e cura a carattere scientifico, Rozzano, Milan, Italy; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Milan, Italy.
Humanitas Clinical and Research Center, Istituto di ricovero e cura a carattere scientifico, Rozzano, Milan, Italy; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Milan, Italy.
出版信息
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2134-2135. doi: 10.1016/j.cgh.2020.04.071. Epub 2020 Apr 30.
Abstract
The first cases of COVID-19 infection were reported in December, 2019, in Wuhan, China. Italy (in particular Lombardy) and France (in particular Northeast) have been gravely hit. Both physicians and inflammatory bowel disease (IBD) patients are deeply concerned that immunosuppressants or biologics may increase the risk of COVID-19 infection. IOIBD has put in place an international registry, SECURE-IBD, for tracking all the cases with IBDs infected by COVID-19 (SECURE-IBD registry: http://www.covidibd.org). It will describe the outcomes of infected patients and the association between IBD-related medications and these outcomes.
摘要
2019 年 12 月，中国武汉首次报告了 COVID-19 感染病例。意大利（特别是伦巴第大区）和法国（特别是东北部）受到了严重打击。医生和炎症性肠病（IBD）患者都非常担心免疫抑制剂或生物制剂可能会增加 COVID-19 感染的风险。IOIBD 已经建立了一个国际注册中心 SECURE-IBD，用于跟踪所有感染 COVID-19 的 IBD 患者（SECURE-IBD 注册中心：http://www.covidibd.org）。它将描述感染患者的结局以及 IBD 相关药物与这些结局之间的关联。
相似文献
1
Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts.《来自南锡和米兰队列的炎症性肠病患者的 COVID-19 发病和模式》。
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2134-2135. doi: 10.1016/j.cgh.2020.04.071. Epub 2020 Apr 30.
2
Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry.新冠疫情时代的数据可视化：SECURE-IBD注册研究的交互式地图
Am J Gastroenterol. 2020 Nov;115(11):1923-1924. doi: 10.14309/ajg.0000000000000953.
3
Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic.COVID-19 大流行期间需要住院治疗的 IBD 患者的护理。
J Crohns Colitis. 2020 Oct 21;14(14 Suppl 3):S774-S779. doi: 10.1093/ecco-jcc/jjaa150.
4
5
IBD in the COVID-19 era: the value of international collaboration.新冠疫情时代的炎症性肠病：国际合作的价值
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):887-888. doi: 10.1016/S2468-1253(20)30269-7.
6
Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19.COVID-19 期间停用免疫抑制剂药物的炎症性肠病患者重启治疗的指导意见。
J Crohns Colitis. 2020 Oct 21;14(14 Suppl 3):S769-S773. doi: 10.1093/ecco-jcc/jjaa135.
7
Changes in the spatial distribution of COVID-19 incidence in Italy using GIS-based maps.利用基于地理信息系统的地图分析意大利新冠肺炎发病率的空间分布变化。
Ann Clin Microbiol Antimicrob. 2020 Jul 18;19(1):30. doi: 10.1186/s12941-020-00373-z.
8
Covid-19 Outbreak Progression in Italian Regions: Approaching the Peak by the End of March in Northern Italy and First Week of April in Southern Italy.意大利各地区的新冠疫情进展：北部地区将于 3 月底达到高峰，南部地区将于 4 月初达到高峰。
Int J Environ Res Public Health. 2020 Apr 27;17(9):3025. doi: 10.3390/ijerph17093025.
9
Challenges in paediatric inflammatory bowel diseases in the COVID-19 time.新冠疫情期间儿童炎症性肠病面临的挑战
Dig Liver Dis. 2020 May;52(5):593-594. doi: 10.1016/j.dld.2020.03.015. Epub 2020 Apr 8.
10
SARS-CoV-2 was already spreading in France in late December 2019.SARS-CoV-2 已于 2019 年 12 月在法国传播。
Int J Antimicrob Agents. 2020 Jun;55(6):106006. doi: 10.1016/j.ijantimicag.2020.106006. Epub 2020 May 3.
引用本文的文献
1
Inflammatory bowel diseases during the COVID-19 pandemic.新冠疫情期间的炎症性肠病
Prz Gastroenterol. 2024;19(3):231-235. doi: 10.5114/pg.2024.143143. Epub 2024 Sep 18.
2
Impact of Mild COVID-19 History on Oral-Gut Microbiota and Serum Metabolomics in Adult Patients with Crohn's Disease: Potential Beneficial Effects.轻度新冠病史对成年克罗恩病患者口腔-肠道微生物群和血清代谢组学的影响：潜在益处
Biomedicines. 2024 Sep 14;12(9):2103. doi: 10.3390/biomedicines12092103.
3
Incidence of Severe COVID-19 Outcomes and Immunization Rates in Apulian Individuals with Inflammatory Bowel Disease: A Retrospective Cohort Study.普利亚地区炎症性肠病患者中重症 COVID-19 结局的发生率及免疫接种率：一项回顾性队列研究
Vaccines (Basel). 2024 Aug 2;12(8):881. doi: 10.3390/vaccines12080881.
4
The Worries of Out-of-Home Activities in Patients With Inflammatory Bowel Disease: A Survey Study During the COVID-19 Pandemic.炎症性肠病患者户外出行活动的担忧：一项在新冠疫情期间的调查研究
Gastroenterol Res Pract. 2024 Jul 3;2024:6634377. doi: 10.1155/2024/6634377. eCollection 2024.
5
SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients - does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study.炎症性肠病（IBD）患者的新型冠状病毒2型（SARS-CoV-2）疫苗接种——IBD治疗是否会对SARS-CoV-2抗体产生负面影响？一项单中心前瞻性研究。
Prz Gastroenterol. 2024;19(2):198-205. doi: 10.5114/pg.2023.130126. Epub 2023 Jul 27.
6
Clinical characteristics and the risk factors for the exacerbation of symptoms in patients with inflammatory bowel disease during the COVID-19 pandemic.COVID-19大流行期间炎症性肠病患者的临床特征及症状加重的危险因素
Front Med (Lausanne). 2024 Jun 5;11:1404880. doi: 10.3389/fmed.2024.1404880. eCollection 2024.
7
Inflammatory bowel diseases and the clinical course of coronavirus disease 2019 - a Polish single-centre experience from the pre-vaccine era.炎症性肠病与2019冠状病毒病的临床病程——波兰疫苗接种前时代的单中心经验
Prz Gastroenterol. 2023;18(4):409-415. doi: 10.5114/pg.2023.133479. Epub 2023 Dec 8.
8
The association between ulcerative colitis and COVID-19 severity: a systematic review and meta-analysis systematic review.溃疡性结肠炎与 COVID-19 严重程度的关联：系统评价和荟萃分析。
Int J Colorectal Dis. 2023 Dec 18;39(1):5. doi: 10.1007/s00384-023-04568-6.
9
SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis.炎症性肠病患者新冠疫苗接种后出现的新冠病毒突破性感染：一项系统评价与荟萃分析
Therap Adv Gastroenterol. 2023 Jul 15;16:17562848231174295. doi: 10.1177/17562848231174295. eCollection 2023.
10
Prevalence and complication of COVID-19 in patients with ankylosing spondylitis (AS) and its relationship with TNF-a inhibitors.COVID-19 的患病率和并发症在强直性脊柱炎（AS）患者及其与 TNF-a 抑制剂的关系。
Immun Inflamm Dis. 2023 Jun;11(6):e915. doi: 10.1002/iid3.915.
本文引用的文献
1
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
2
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.新型冠状病毒肺炎（SARS-CoV-2）感染的癌症患者：一项中国全国性分析。
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
3
Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission.中东呼吸综合征冠状病毒：原发性、家庭和医院传播的风险因素和决定因素。
Lancet Infect Dis. 2018 Aug;18(8):e217-e227. doi: 10.1016/S1473-3099(18)30127-0. Epub 2018 Apr 18.
4
Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.炎症性肠病治疗相关的严重和机会性感染风险。
Gastroenterology. 2018 Aug;155(2):337-346.e10. doi: 10.1053/j.gastro.2018.04.012. Epub 2018 Apr 12.
Zotero 插件